Sign In
Buy EXEL
$51.60
+3.06 (+6.30%)
At Close: Jun 03, 2026
Recap: Exelixis Q2 Earnings
06:01pm, Thursday, 05'th Aug 2021
Shares of Exelixis (NASDAQ:EXEL) moved higher in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 48.00% year over year to $0.37, which beat the e
New Strong Sell Stocks for July 27th
10:44am, Tuesday, 27'th Jul 2021
ARR, BCC, DK, EXEL and FCCO have been added to the Zacks Rank #5 (Strong Sell) List on July 27, 2021.
The Smartest Stocks to Buy With $20 in July
05:51am, Friday, 16'th Jul 2021
You don't need a lot of cash to begin or further your trek toward financial independence.
After Plummeting More Than 23%, Is Exelixis a Buy?
07:41am, Friday, 09'th Jul 2021
The market may have overreacted to weak clinical trial data, but its pessimism wasn't entirely misplaced.
Is Exelixis Stock a Buy After Its Disappointing Liver Cancer Study Results?
06:55am, Friday, 09'th Jul 2021
The biotech stock plunged after disappointing clinical results.
The Smartest Stocks to Buy With $100 for the Second Half of 2021
05:51am, Friday, 02'nd Jul 2021
You don't need to start with a fortune to make one on Wall Street.
Exelixis (EXEL) Down on Data From Ongoing Liver Cancer Study
07:41pm, Tuesday, 29'th Jun 2021
Exelixis (EXEL) and partner announce unimpressive data from the late-stage COSMIC-312 study in patients with previously untreated advanced hepatocellular carcinoma.
Here's Why Exelixis Stock Is Dropping Today
12:04pm, Monday, 28'th Jun 2021
The company reported successful clinical trial results, but investors were still disappointed.
EXEL Stock Price Falls Over 10% Pre-Market: Why It Happened
09:21am, Monday, 28'th Jun 2021
The stock price of Exelixis, Inc. (NASDAQ: EXEL) fell by over 10% pre-market. This is why it happened.
Exelixis Shares Drop On Mixed Results For Cabometyx Combo In Early Liver Cancer
08:40am, Monday, 28'th Jun 2021
Exelixis Inc (NASDAQ: EXEL) and Ipsen (OTC: IPSEY) have announced mixed interim results from the COSMIC-312 Phase 3 trial evaluating cabozantinib (Cabometyx) in combination with Roche Holding AG
ALAMEDA, Calif. & PARIS--(BUSINESS WIRE)--Regulatory News: Exelixis, Inc. (NASDAQ: EXEL) and Ipsen (Euronext: IPN; ADR: IPSEY) today announced that COSMIC-312, the ongoing phase 3 pivotal trial evalua
The Smartest Stocks to Buy With $100 Right Now
05:51am, Friday, 18'th Jun 2021
You don't need a boatload of money to chart a path to financial freedom.
Exelixis (EXEL) & Bristol Myers Team Up for Genitourinary Cancers
12:47pm, Tuesday, 15'th Jun 2021
Exelixis (EXEL) collaborates with Bristol Myers to evaluate its next-generation tyrosine kinase inhibitor in combination with immuno-oncology therapies in advanced solid tumors.
Tuesday Analyst Upgrades and Downgrades: Campbell Soup, Exact Sciences, Exelixis, Spirit Airlines, Sarepta, ZTO and More
09:11am, Tuesday, 15'th Jun 2021
Tuesday's futures were fairly positive after a somewhat mixed start to the week.
Here's What Crushed Exelixis' Earnings
10:06am, Sunday, 06'th Jun 2021
R&D spending is hurting earnings, but long-term investors shouldn't be worried.
